A ROADMAP TO METROLOGY READINESS FOR INFECTIOUS DISEASE PANDEMIC RESPONSE

CCQM
Measurement is an essential tool in the assurance of delivery of healthcare.

Diagnostic testing for SARS-CoV-2 has been imperative for identifying and managing infected individuals, contact tracing, epidemiologic characterisation and public health decision-making at the national and international level throughout the COVID-19 pandemic.

The unpredictability surrounding the time of onset and the type of pathogen that will cause the next pandemic emphasizes the need for lessons to be learnt from the COVID-19 pandemic and provision of pandemic preparedness plans for future health emergencies, especially for:

- greater understanding of pathogens, their evolution and circulation for early identification of infectious threats, particularly through increased global systemic genomic sequencing capacity and rapid sharing of data, including meta-data
- implementation of standardized test requirements for in vitro diagnostic (IVD) devices, including quality requirements and assay design principles
- development of a collection of diagnostics, therapeutics and vaccines (DTVs) for early deployment to infectious threats, demonstrated through a well-rehearsed action plan.

The metrology community successfully provided international reference measurement system procedures and materials for molecular and serological testing within months of isolation of SARS-CoV-2. It also more generally supported testing capability for wider stakeholders, albeit to different and largely national extents throughout the world.

However, its contributions were often not pro-actively sought by wider stakeholders and under-represented in decision-making based on measurement, due to an over-arching lack of awareness of the benefits to be offered by the metrology community and the lack of an international cohesive presence of the community in infectious diseases allowing:

- a sufficiently fast provision of metrological recommendations (days to weeks)
- a direct link to IVD device producers
- assistance with rapid expansion of testing capacity and capability.

This document identifies priorities and sets out pathways for pandemic preparedness for the metrology community resulting from the 2021 series of CCQM Webinars and Workshop.
Identify measurement priorities and outline pathways needed to provide effective contributions in a timeline appropriate for pandemic response and which raise awareness of the metrology community with wider stakeholders.
The Roadmap provides:

- wider stakeholders with visibility and guidance on the metrology interventions at the technological, platform and infrastructural level available as part of an integrated response to a future pandemic;

- the metrology community with a route for rapid deployment of their response during the critical juncture of a future pandemic, such that better accelerated measurement leads to improved decision-making and faster recovery outcomes.

The Roadmap addresses metrology needs to provide comparable/equivalent diagnostic test measurements that result in the same outcome - traceability is an established way of achieving this in other industries/communities.

The Roadmap does not address metrology for the continuous process of data collection and analysis and its dissemination to policy makers and healthcare and other professionals for public health surveillance, priorities for personal protective equipment (PPE), potential pharmaceutical/medicinal treatments or vaccines.

The Roadmap focus areas:

Understanding pandemic frequency, lifecycles and associated testing challenges.

Characterizing technology challenges necessary to improve readiness and drive down response time and improve clinical evaluation during the different stages of a future pandemic. Summarized short-term and medium-term metrology priorities.

Informed strategies for realizing identified challenges (based on sound science) that will enable a more rapid metrology response, reduce the impact on everyday life and enhance clinical outcomes of any future pandemic:

- Political
- Collaborative
- Technical.

List of contributors and Information sources.
Clinical evaluation of IVD devices extends beyond pathogen targets (nucleic acids, viral proteins and serology) and includes:

- clinical characteristics (such as the viral burden of the patient and the time since exposure or onset of symptoms)
- operational testing attributes (such as specimen type, swab technique and transport conditions, as well as the laboratory technique used)
- analytical test properties (such as sample preparation, signal amplification and data interpretation).

While the race for diagnostic detection of SARS-CoV-2 saw a diverse assortment of technological tests being offered, many of them exhibited varying performance characteristics and limitations for clinical utility in specific use settings. The appropriate interactions of relevant expert analytical scientists, clinicians, risk assessors and public health officials were not optimal. The gaps and assumptions in diagnostic testing were poorly explained and not translated into an uncertainty that could be quantified and monitored throughout the pandemic. The creation and re-purposing of existing capacities for deployment against the COVID-19 pandemic were also exposed by the scale, geographies, timeliness, quality, integration of surveillance and diagnostic needs and comparability of associated clinical measurement data, reflecting a need for co-ordinated systems with sufficient robustness and controls to maximize test accuracy.

The G7 countries and global science leaders have since launched and mobilized the 100 Day Mission (100DM), working with the G20 and wider international partners, the World Health Organization (WHO) through their global genomic surveillance strategy, and the life sciences and biotechnology sectors. The intention is to advise the G7 Presidency on how to develop and deploy safe and effective diagnostics, therapeutics and vaccines within the first 100 days of a pandemic.

Early intervention from a strong and organised international metrology framework able to respond at sufficient pace (days to weeks) to the rapidly emerging future pandemic would have been even more beneficial in supporting national readiness for any such crisis. Deployment of ready-made measurement strategies to optimise safety, speed and ease of infectious disease testing (without compromising accuracy) would have provided robust front-line tests and minimum quality requirements able to deliver results, with the right clinical utility at the right time, faster and would have underpinned better public health predictions through provision of detection limits and uncertainty estimations around utilized measurements.

Such a faster and more coordinated international response would likely reduce public health and economic impacts and costs by:

**Ascertaining performance of diagnostic tests** with respect to identifying which tests are fit for purpose at the different stages of the pandemic and breakthrough infections among vaccinated persons (with or without booster vaccination).

**Addressing the spread of disease** through faster identification and sharing of the pathogen, up-scaling testing, improved data generation for contact tracing, trend analysis, clinical performance assessment and integration of diagnostic testing into routine medical care and enhanced epidemiological prediction tools.

**Identifying subsequent changes in the pathogen** within populations through faster identification of variants.

**Accelerating identification, testing and regulatory review of potential treatments and vaccines** through better tools for disease analysis, innovative clinical trial approaches and regulatory approval pathways.
INTENDED USERS AND BENEFICIARIES

- Metrologists
- Healthcare providers
- Policy makers
- Raw materials suppliers
- Control material (reference standard) manufacturers
- IVD device manufacturers
- Researchers
- Informaticians
- External quality assurance/Proficiency testing providers
- Accreditation bodies
- Notified bodies
The Consultative Committee for Amount of Substance – Metrology in Chemistry and Biology (CCQM),

NOTING
- the importance of internationally comparable and accurate measurements of infectious disease diagnostics for human health
- the response of the international metrology community to the COVID-19 pandemic through the CCQM Nucleic Acid Working Group (NAWG) and Protein Analysis Working Group (PAWG) comparison studies to establish, within months, viral (SARS-CoV-2) and serological (IgG antibody) reference measurement procedures and reference materials
- the technical considerations identified during the 2021 series of CCQM Webinars and Workshop on infectious diseases needed to achieve a centralized strategy for adeptly mobilizing and scaling up appropriate rapidly deployable accurate measurement methods and standards, within days to weeks, which are capable of being deployed to differentiated end-user communities for a future infectious disease pandemic.

RECOMMENDS
- the implementation by CCQM of 'fire drill' comparison exercises, starting in 2022, to demonstrate the international metrology community’s capability for a rapidly deployable response of reference measurement methods and dissemination of equivalent calibration materials for infectious disease diagnostics in support of governments, policy-makers and control material manufacturers and suppliers.

ENCOURAGES
- National Measurement Institutes (NMIs) and associated Designated Institutes (DIs) to initiate collaborative work programmes addressing identified short-term and medium-term technical measurement research activities to establish accurate measurements for a panel of agreed infectious disease pathogens with known uncertainties.

The Consultative Committee for Amount of Substance – Metrology in Chemistry and Biology (CCQM),

NOTING
- the lack of pathways and rigorous guidelines and standards for evidencing assay performance testing that will enable in vitro diagnostic (IVD) device manufacturers to navigate the medical device regulatory approval process more adeptly
- the need for BIPM and the NMIs to develop more intimate working relationships with the infectious disease community and other stakeholders to ensure that international comparability of infectious disease measurements is realized
- the existing memorandum of understanding (MoU) between BIPM and the WHO,

RECOMMENDS
- the establishment of a Task Group (TG) for infectious diseases with metrology working group representatives and other stakeholders, during 2022, to aid:
  - the community design of the ‘fire drill’ comparison exercises
  - shape the planned technical work programme of the metrology community
  - document standardization approaches for prioritized measurands addressed by the international metrology community that can be included in the desirable attributes of safe and effective IVD devices and provide metrology-based evidence to support regulatory decision-makers, for well-defined clinical situations across the lifecycle of a pandemic.

The Consultative Committee for Amount of Substance – Metrology in Chemistry and Biology (CCQM),

NOTING
- the BIPM and the NMIs need to ensure knowledge transfer and training such that existing national and regional health response interventions are available in the event of any future pandemic,

RECOMMENDS
- the establishment of a Task Group (TG) including representation from Regional Metrology Organisations (RMOs) to:
  - develop eLearning modules on metrology for infectious diseases, deployable via the BIPM eLearning platform
  - facilitate RMO capability maintenance/development
  - guide community users, particularly in clinical settings to adopt clearly defined measurement units for the purposes of laboratory comparisons
  - provide metrology-based evidence to support regulatory decision-makers
  - develop a paper on facilitating a more agile metrology workforce able to pivot to pandemic response when required.
The frequency of emergence and spread of infectious diseases, such as zoonotic influenza, emerging coronaviruses and viral hemorrhagic fevers, have been increasing steadily through transmission of pathogens to humans.

Global surveillance programmes of water-borne pathogens, vector-borne diseases and zoonotic spillovers at the animal-human interface continue to be of prime importance to detect, rapidly, the emergence of infectious threats. The implementation of public health measures (such as isolation, quarantine and border control) along with technological development and advances in pharmaceutical interventions have helped largely to contain the spread of such infectious diseases – at least until recently. Nonetheless certain classes of infectious diseases, such as seasonal influenza, malaria, syphilis and human immunodeficiency virus (HIV)/AIDS continue to remain endemic and, as illustrated by pandemic influenza and monkeypox, have the potential to spread.

Schematics showing timelines of historical pandemics over the last 100 years. A. Numbers of infected and deceased in different pandemics. B. Numbers of infected and deceased in the first 7 months of the SARS-CoV-2 pandemic. C. Evolution and recurrence of influenza A virus subtypes over the last 100 years.

https://doi.org/10.3389/fmicb.2020.631736

https://doi.org/10.1038/s41893-020-00605-2

https://doi.org/10.3389/fmicb.2020.031736
Three parameters are important in describing the dynamics of a pathogen: the basic reproduction number (R) which determines the rate at which the pathogen is likely to spread in the population, the threshold number of hosts required for the pathogen to become established and the mean levels of infection in the host population. On the latter point, no current technology can accurately and rapidly measure the number/quantity of infectious virus particles. This leaves the need to understand the gaps between what can be measured, copies of RNA/DNA/protein and what is intended to be measured, including units of measurement and their comparison. It is also important to be aware that insufficient emphasis placed on the intended use of the different tests raises the risk of the tests being used inappropriately. Furthermore, diagnostic performance may change relative to the effective R number; the disparities between patient populations across time being an important consideration.

Schematic to illustrate examples of how the proportions of COVID-19 patients are distributed among the different stages of SARS-CoV-2 infection when the effective reproduction number, R >1 (red line) and <1 (green line). The grey dashed line represents an endemic equilibrium state, where R = 1. Also shown is an example of the change in viral burden (black line) with time since symptom onset. When the infection is spreading and R>1, there are more patients of the total who are at an earlier stage in their infection - as high viral burden occurs earlier in the infection there are also more patients with higher viral burden. The reverse is the case when R<1. This will result in a change in diagnostic performance (manifesting as a clinical sensitivity shift) when using quantitative thresholds or analytically less-sensitive methods.

Recently, enveloped RNA viruses that are distributed broadly in animals have been identified in birds and mammals, including humans. These coronaviruses have a genome which is the largest among all RNA viruses. Six coronaviruses have been associated with human disease: SARS-CoV-1, MERS-CoV, human coronavirus 229E (HCoV-229E), human coronavirus OC43 (HCoV-OC43), human coronavirus NL63 (HCoV-NL63), and human coronavirus HKU1 (HCoV-HKU1).

The latest observed coronavirus, SARS-CoV-2, is a beta-coronavirus. The cell surface receptor for this virus is the angiotensin-converting enzyme 2 (ACE2), involved in regulation of cardiac function and blood pressure and expressed in epithelial cells of its primary lung and small intestine targets, as well as in heart, kidney and other tissues. SARS-CoV-2 replication in the upper and lower respiratory tract allows transmission by droplets and aerosols. The median incubation period for the original virus was 5.7 (range 2–14) days, similar to SARS-CoV-1 and MERS; albeit the latest predominant variants of the virus reduced this significantly. Most infections have been uncomplicated, but 5–10% of patients needed hospitalization, mainly due to pneumonia with severe inflammation. Severe respiratory and multi-organ failure complications were observed in a number of cases, their likelihood being based on a number of risk factors, including immunodeficiency.

Hence, while only 3 weeks elapsed from visualization of the SARS-CoV-2 virus to elucidation of its genetic sequence, compared to the 5 months for its predecessor SARS-CoV-1, the emergence, spread and effect of SARS-CoV-2 was felt worldwide, with over 1 million confirmed cases and 100,000 deaths within 3-4 months of initial reported pneumonia cases (later named COVID-19) in Wuhan.

At the time of publication of this Roadmap (5 August 2022), global confirmed COVID-19 cases according to the World Health Organization (WHO) have reached ~579.1 million with ~6.4 million attributed deaths.
Diagnostic approaches for pathogens can be divided into two broad categories. Clinical diagnostics include symptoms, laboratory markers not specific to the pathogen of concern and imaging technology, all of which may be indicative of the pathogen. In vitro diagnostics provides more definitive evidence and are essential for patient management and outbreak control. Acceptable design, development and quality of in vitro diagnostic methods is critical to ensuring control of the spread and impact of the pathogen and remains the preferred confirmatory diagnostic in the early stages of a pandemic. The lessons learned from the SARS-CoV-1 outbreak clearly guided SARS-CoV-2 detection strategies, with researchers able to adapt established diagnostic technologies.

Laboratory confirmation testing for pandemics typically use nucleic acid amplification tests (NAATs) (more specifically reverse transcription polymerase chain reaction (RT-qPCR) assays), with ‘sample-to-answer’ platforms (including high-throughput systems and rapid point of care assays) being employed to increase testing capacity. As NAATs are highly sensitive, they can remain positive for some weeks after infection, whereas viral culture studies (for SARS-CoV-2) suggest replication of the virus for only a week or two after symptom onset.

Antigen- and antibody-based assays can complement NAATs. Antigen-capture methods that rapidly detect (15-30 mins) protein fragments on or within the virus are routinely used for assays for HIV and hepatitis B virus and were employed for SARS-CoV-1 and MERS. These Ag-RDT methods for SARS-CoV-2 offered rapid identification of highly infectious cases (typically 5-12 days after onset of infectious symptoms), providing information about potential transmissibility and enabling targeted isolation and tracking of infectious cases and contacts, and correlation with disease severity and death. Experience from their performance during the H1N1 pandemic suggested sub-optimal sensitivity was to be expected, given the lack of pre-amplification of the target analyte and higher limit of detection (LOD) of these tests.

Their different performance in diagnostic studies rather than in the real-world merits further evaluation, but greater emphasis on post-market surveillance ensures that medical devices continue to be safe and perform well when placed on the market and that actions are undertaken if the risk of continued use of the device outweighs the benefit. Support for evaluation of such surveillance can highlight opportunities to improve the device where users report them to be ‘not working’.

Measurement of specific serological antibodies can be used to assess pathogen exposure and infer potential immunity. Antibody serology is particularly useful for research and surveillance, but accurate interpretation of such testing depends on antigen specificity and the antibody isotype detected. Generally, IgG is more specific and may appear later in infection, but specific humoral responses are dominated by IgA antibodies. Anti-HIV is used widely for screening and to aid diagnosis of HIV but in the COVID-19 pandemic, antibody assays proved sub-optimal for diagnosis due to the delays in seroconversion and variability in performance. Antibody specificity and kinetics, particularly in the setting of re-infection, merits further investigation.

Preliminary findings suggest that a person’s genetic makeup may play some role in determining their risk of getting, or having severe outcomes, from COVID-19. However, any direct correlation has yet to be validated.

Genomic sequencing techniques are needed for the identification and monitoring of variants of concern (VOC) and variants under investigation (VUI) for SARS-CoV-2. However, while recognizing its specialized contribution, genomic surveillance comes at a high cost technically, especially in resource-limited settings. Nonetheless, there is the opportunity to embed genomic sequencing capacity at the national level and to integrate it with other disease surveillance systems for future broader zoonotic disease surveillance, evaluation of changes in the pathogen genome over time and for tracing patterns of transmission.

Despite current approaches for the ever-expanding array of available tests, the SARS-CoV-2 pandemic has highlighted the differences between theoretical sensitivity/specificity values for many of the available diagnostic tests and diagnostic sensitivity/specificity values in given patient populations; the majority requiring further validation around these values, speed, ease of use and their deployability.
CHARACTERIZING TECHNOLOGY CHALLENGES
Virus and viral variants

Virus

Robust viable culture of pathogen material is reliant on correct storage of the original samples, re-sampling or early detection and prompt collection of retained material, particularly in high and low prevalence scenarios. Such material cannot be shared readily, in a timely manner, across borders, their successful culture is not guaranteed and yet their management is a priority for clinical and epidemiological control of the pathogen. Future resilience through established and maintained distribution networks to ensure widespread dissemination of relevant material is essential. Resultingly, where inactivation procedures are necessary or contrived samples employed, assurance of comparability with ‘live’ material is necessary. With frequent horizon scanning, it should be possible to culture and produce variant materials in advance of those variants becoming widespread.

Advanced sequencing protocols based on Sanger, next-generation sequencing (NGS) (e.g. Illumina) and MinION/Nanopore, are increasingly being applied to generate genome sequences rapidly, with the promise that data will inform diagnostic development, epidemiologic investigations, host-pathogen interactions, pathogen evolution (mutation with associated transmissibility and/or virulence effect), pathogenesis, and prevention and treatment targets. NGS can also be used to evaluate the host microbiome and coinfection with certain pathogens, but its cost to date has limited its use for research purposes rather than clinical management.

Complimentary to sequencing, genotyping also offers rapid and cost-effective data.

Standard material requirements:

- Rapid access to ‘wild type’ and variant materials for genotyping VOC performance monitoring and sequencing, and external quality assurance and accreditation purposes
- Clinical access to circulating strains is dependent on prevalence, public co-operation and testing strategies
- Availability of agreed reference strains (including sequences) for control and validation and verification materials, and in silico analysis
- Availability of materials and methods appropriate for genetic diversity (fast production)
- Reference measurement procedures for quantity and identity
- Comparability and commutability of contrived or surrogate commercial synthetic controls for validation, verification and assessment of molecular and antigen assays (samples to range from pure proteins to synthetic RNA constructs)
- Need for samples that reflect the heterogeneity of clinical samples in the format that has been validated by manufacturers for regulatory purposes.

Identified challenges:

- Rapid access to standardised, characterised and quantified cultured material in formats that are suitable for the end-user
- Some tests are manufactured and sold solely nationally so that, internationally, VOC/VUI performance is unknown
- Internationally standardised methods to validate, verify and assess assays for true comparability
- Comparison of materials using a range of units suitable for multiple technologies and assay types, such as copies/mL, PFU/mL
- Stop reliance on Cq values for indicative viral loads, performance comparison and selection of samples for genotyping and sequencing, rather than true LOD.
Molecular and antigen technologies

Nucleic acid amplification methods

RNA can be highly susceptible to degradation - sample storage, handling and RNA isolation must follow optimized protocols to minimize degradation at each step. Targets should be highly conserved genes of the virus. Use of multiple PCR targets helps to avoid false negatives associated with mutations in the primer site region, but they require regular review and possible updating as is the case with influenza.

Furthermore, viral RNA detection by combining RT (to generate a complementary DNA copy of the viral RNA sequence) with qPCR (RT-qPCR) does not necessarily demonstrate the presence of infectious virus, as patients who have recovered from infection can be more persistently PCR-positive.

RT-qPCR enables (typically) a fluorescent detection of labelled target nucleic acid sequence. The output is the Cq value as termed by the Minimum Information for Publication of Quantitative Real-Time PCR Experiments (MIQE) guidelines, but also referred to as cycle threshold (Ct) or crossing point (Cp). Quantification is performed following a user-applied calibration step involving a reference calibrator of known concentration for the RT-qPCR – the quantitative relationship between Cq value and calibrator copies being established based on the gradients of each standard setting the standard curve. Reported associations between Cq values and ability to correlate SARS-CoV-2 virus and patient outcome, along with other factors such as symptoms, have led to Cq values being used by physicians to guide decisions pertaining to individual patients. However, Cq is an arbitrary unit, not transferable without access to the same reagents, protocols and calibrators; there is reported variability in Cq between the same devices, variability in Cq between different devices, an increasing view from manufacturers that the ‘user’ calls the Cq, some devices do not report Cq and there is observed irregularity in calling ‘positive’ between test sites (based on one or two targets being reported ‘positive’). High rates of false positive SARS-CoV-2 have been attributed to specimens with high Cq values being interpreted as SARS-CoV-2 positive, both on and off label. Thus, while the concept of using Cq as a threshold for risk based on viral burden is logical such variation, combined additionally with low viral copy number at stages in the disease progression and undetermined potential errors surrounding sampling collection, may engender differences in absolute Cq values (Cq is log base 2 and so small changes give large concentration changes).

Consequently, it would seem using Cq thresholds to quantify SARS-CoV-2 burden, stratify risk and aid patient management would be challenging, while also problematic if used to discuss broader analytical performance or as a measure to guide the development of IVDs.

Interestingly, Cq has not typically been applied in such a way when managing other viral infections, despite clinical virology arguably representing the medical field that most broadly applies accurate molecular quantification for managing patients based on nucleic acid quantity.

Reverse transcription digital PCR (RT-dPCR) uses the same reagents as RT-qPCR, but applies limiting dilution, endpoint PCR and Poisson statistics to give a direct estimate of concentration. Consequently, such quantification overcomes normalization and calibrator issues, being less affected by bias resulting from repeatability and reproducibility errors. This technology has been used for analysis of absolute DNA copy number (and RNA copy number with knowledge of the efficiency of the reverse transcription step) from clinical samples and has been demonstrated to provide improved assay reproducibility when compared to RT-qPCR for detection and quantification of SARS-CoV-2 RNA from purified RNA and crude lysate samples. Further guidance on the use of qPCR and dPCR can be found in ISO 20395. Calibrated copy-based units (used elsewhere in virology) clearly offer a more reproducible alternative to Cq values.

Isothermal amplification methods offer an alternative strategy for detecting virus-infected patients, as they do not require use of thermocycling equipment.

A current list of isothermal methods applied to SARS-CoV2 can be found in ISO/TS 5798.

While PCR-based approaches are most widely used for confirmatory diagnosis, loop-mediated isothermal amplification (LAMP), and when combined with reverse transcription (RT-LAMP), needs only heating and visual monitoring and has a sample-to-result time of around 1 h.

RT-LAMP uses 4-6 primers to prime DNA polymerase that displaces existing complementary strands, making them available for further binding of other primers. Internal primers are designed to bind and prime DNA synthesis while also containing a sequence at the five prime end that is complementary to the sequence downstream of the primer. Consequently, when a single-stranded molecule is formed due to displacement following priming of an upstream primer, a hairpin is formed. Loop primers bind the hairpin structures and can speed up the process. RT-LAMP methods combine both steps into a single reaction.
Antigen detection methods

Antigen-based diagnostics are attractive as a potential point of care diagnostic, detecting protein fragments on or within the pathogen (rather than viral nucleic acids) within 15 mins (compared to hours by qPCR). Viral proteins detected by antigen-capture methods (such as antibodies or aptamers) are used routinely for other pathogen assays, such as HIV and hepatitis B virus. When their performance is acceptable, rapid antigen tests can reduce transmission through early detection of highly infectious cases, enabling implementation of targeted isolation and tracking of infectious cases and contacts.

However, for SARS-CoV-2, swab samples showed excellent specificity but varying overall sensitivity, with higher viral burden associated with better sensitivity. This is analogous to the performance of the influenza antigen test in the H1N1 pandemic, where specificity was excellent but sensitivity low.

Further studies are needed to determine the performance of these assays and their clinical utility, especially with regards to emerging variants.

Identified challenges for deployment:

- Fast production (days to weeks) of a standard control material: does not need to be perfect, but what are acceptable limitations?
- Synthetic target panels and other routes for quality assurance (including failure)
- Quality assurance for pre-examination stages (e.g. different swab types and locations, different specimens etc.): comparison studies
- Panels for specificity
- Materials for internal controls
- Reference measurement procedures
- Routes for improved guidance: (e.g. minimum validation criteria etc.)
- Materials to support mass testing (e.g. point of care, high throughput etc.)
- Routes to allow in vitro diagnostic device manufacturers, physical standard providers and regulators to better interact.

Identified challenges for measurement research:

- Improved accuracy of viral burden measurement methods, with clearly defined units and an idea of how they compare (education)
- Data uncertainty needs to be accounted for, particularly to inform more robust evidence-based policy-making
- Routes to understand the differences between detecting viral presence (RNA vs protein) and infectivity (replicative intermediates, pathogen/disease progression)
- Impact of VOC and VUI on testing
- Commutability of reference/standard materials
- Quality management approaches for test provision by lay or non-laboratory trained healthcare professionals
- Routes to ensure safety.
Serologic measurement of specific antibodies can be used to assess prior exposure to virus and to infer potential immunity. Antibody serology as a diagnostic tool is particularly useful for patients with delayed clinical presentation. Serological data is particularly useful for epidemiologic purposes and to evaluate the impact of control measures (lockdowns, broad testing, and other policies). Antibody evaluation can also facilitate identification of plasma donors and assessment of vaccine immunogenicity, especially in elderly or otherwise immunocompromised people.

Cross-reactivity between antibodies to the pathogen and other endemic human pathogens may enable design of pan-pathogen therapeutics or vaccines.

Serological surveillance may identify potential zoonotic disease transmission from wildlife reservoirs, such as bat-borne coronavirus and influenza virus (e.g. H1N1).

For coronaviruses, the spike (S) and nucleocapsid (N) proteins are the primary viral antigens used for antibody assays. The N gene is reportedly more conserved and stable than the S gene, and available S-based assays measure total binding antibodies rather than only neutralizing antibodies. Neutralising antibodies are measured conventionally by the plaque reduction neutralization test (PRNT), requiring specialized containment facilities and 2–4d to complete. Whilst a pseudovirus neutralization test (pVNT) offers a more practicable alternative, utilizing genetically-modified pseudovirus that mimics the real pathogen requires comparative study with the PRNT assay and the optimal class of pseudovirus is needed to ensure suitable validation of the pVNT assay.

Several point mutations have demonstrated the ability of pathogens to escape neutralization by convalescent sera and monoclonal antibodies. Hence further studies are needed to characterize antibody dynamics and determine specific antigen suitability for monitoring and surveillance purposes.

Therefore, in a pandemic context where early diagnosis is essential for patient management and outbreak control, antibody assays are sub-optimal due to delayed seroconversion and performance variability.

**Identified challenges:**

- Sourcing good quality material of the target proteins (spike and nucleocapsid protein) to produce high quality antibodies
- Determining which systems are most suitable to produce different antibodies? - for the N-protein bacterial cells are suitable; for the highly glycosylated S-protein, human cells are required
- Ensuring calibration of enzyme-linked immunosorbent assays (ELISA) for serology
- Determining what kind of samples can be measured? - dried blood spots (convenient for screening) or plasma samples
- Development and harmonization of quantitative serological assays for antibodies (using conversion factors for assay unitage) pivotal in evaluating immunization status
- Determining the characteristics of seropanels
- Determining the differing behaviours of neutralizing assays and binding assays as they may have different targets
- Identifying a commutable physical standard for all assays that target the same measurand: use of a standard has been shown to improve the comparability of neutralization assays for SARS-CoV-2 but not of binding assays.
- Standardization of high-quality target proteins, antibodies or whole pathogen material, which may be too time consuming in the midst of a pandemic but must be available to ensure constant quality of measurements during any pandemic
- Determining, when antibodies are measured in human plasma, what the result really means in terms of immune response to the pathogen
Emerging prognostic technologies

Biomarkers play a pivotal role in the early detection of disease etiology, diagnosis, treatment and prognosis. Clinical biomarkers are the measurable biological indicators of the presence, severity or type of disease in medical settings. Prognostic biomarkers are a clinical or biological characteristic that provides information on the likely patient health outcome, irrespective of treatment, and frequently serve as useful predictors for development of severe disease.

The use of proteomics for the study of various aspects of infectious diseases worldwide is relatively new, although this approach identified and described proteins and antigenic proteins of the SARS-CoV-1 and the ACE2 protein as the main receptor for SARS-CoV-2 in humans. Recently, the technique has been used in the study of COVID-19 disease through profiling of pathogen-infected human cells, comparative profiling of infected cells versus normal cells and clinical proteomics of COVID-19-positive patients. The approach has become readily automatable, sensitive enough to detect infectious patients (on similar amounts of sample compared to RT-qPCR) and can easily be multiplexed to detect several pathogens in a single run. The potential targeting of multiple pathogens and blood biomarkers simultaneously makes it a promising early warning technique.

Sensing technologies too are changing the landscape of infectious disease detection. Immuno-biosensing is based on the microfluidic flow of biological fluid with detection of any antigen-antibody interaction by way of a change in capacitance. Other types of biosensors use carbon nanotubes to enhance the signal and sensitivity levels of biomarker disease detection. Electrical immuno-sensing helps with sensitivity issues. Many such assays provide only a qualitative method of biomarker detection through an observable colour change.

One of the key problems (medically and in terms of long-term economic burden) is understanding the immune-metabolic underpinnings of Long-COVID and creating clinically actionable strategies for its mitigation. Common laboratory findings amongst COVID-19 patients have included leukopenia, lymphopenia and elevated levels of aminotransaminase, lactate dehydrogenase (LDH) and inflammatory markers (e.g. ferritin, C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)). High D-dimer levels, severe lymphopenia, increased neutrophil to lymphocyte ratio, marked thrombocytopenia, hypoalbuminemia, elevated interleukin IL-6, procalcitonin, cardiac troponin I, and serum amyloid A have been associated with critical illness or mortality in COVID-19. Nonetheless, just three biomarkers have showed sensitivity and specificity values of >50%: a decrease in the lymphocyte count and increases in the inflammatory markers CRP and IL-6.

Identified issues:

- More academic attention to driving technology development with little consideration to what question is being asked and what is fit for purpose for subsequent translation, e.g. diagnosis, rapid screening, patient stratification, prognosis, surveillance, deployment etc
- Lack of definition of the measurand and measurement units (number virus particles, number of infectious virus particles, copies of RNA, Cq, PFU) and comparison between different units.

Metrology challenges:

- Early engagement of the metrology community in the production of matrix reference materials and method validation during transfer of developing methods from academic settings into routine clinical laboratories
- Internal quality controls for clinical trial type biomarker discovery studies seem to be functioning well, even in multi-platform centres: focus should lie with standardization of the relatively small number of emerging biomarker targets, assuming their long-term use is predicted (e.g. lipoproteins, lipids, peptides, volatiles etc)
- Support increasing standardization/harmonization of practices for routine use (especially for breath analysis).
SUMMARIZED SHORT- AND MEDIUM-TERM METROLOGY PRIORITIES

Short-term priorities:

• Establish a legacy reference measurement infrastructure for prioritised infectious disease diagnostics, through clear definition of the measurand, (SI) units of measurement (and their comparison with current practice), limits of detection, clinical sensitivity and specificity, and estimation of measurement uncertainty, with associated common data collection and comparable reporting standards across technology platforms, geographies or demographic groups (further information on metrological traceability can be found in ISO 17511)

• Establish reference method procedures and (commutable) matrix control panels (nucleic acids, proteins and whole pathogens) against common pathogenic agents to facilitate smooth workflows through the lifecycle of a pandemic, and their correlation with infectivity levels

• Establish characteristics to guide development and evaluation of diagnostic testing approaches with low LOD and investigate clinical sensitivity shifts on diagnostic performance benchmarks

• Support continual review of the impact of VOC and VUI on applicability of diagnostic tests.

Medium-term priorities:

• Establish measurement variation with different specimen types and routes to control error from pre-analytical stages of testing

• Develop statistical models using clinical reference data sets to provide alternative routes for diagnostic evaluation

• Prioritise emerging biomarker targets for reference/standard material production, where long-term use can be predicted

• Adaptation of existing workflows to enable a rapid feedback workflow that enables transfer of emerging technologies from research to routine clinical laboratories; particularly considering the role for advanced data analytics to reduce or eliminate false positive events

• Adaptation of a quality management system approach for at, or near to, point of care testing and in community settings necessitating lay or non-laboratory trained healthcare professional test provision.
### LIST OF CONTRIBUTORS AND INFORMATION SOURCES

**25 MARCH 2021**

**CCQM Webinar (3): Ensuring reliability of measurements in response to the Covid-19 Pandemic**

**Dr Naomi Park**  
Setting up high throughput SARS-CoV-2 surveillance sequencing at the Sanger Institute

**Dr Thierry Rose**  
Developing novel high-throughput tests for SARS-CoV-2 antigens and standardization challenges

**Prof. Jo Vandesompele**  
Addressing the challenges of high-throughput SARS-CoV-2 RT-qPCR testing.

**10 DECEMBER 2020**

**CCQM Webinar (2): Ensuring reliability of measurements in response to the COVID-19 pandemic**

**Prof. Maria Zambon**  
Molecular testing for SARS-CoV-2: standardization, challenges and needs

**Dr Corine Geurts van Kessel**  
Validation and implementation of rapid antigen testing for detecting SARS-CoV-2 infection

**Dr Hans Vissers**  
Experiences from MS-based projects for SARS-CoV-2 detection.

**7 JULY 2020**

**CCQM Webinar (1): Ensuring reliability of measurements in response to the COVID-19 pandemic**

**Prof. Jacob Moran-Gilad**  
COVID-19 Diagnostics: from measurement to policy

**Prof. Dr Heinz Zeichhardt**  
Molecular Diagnostics: International proficiency testing as basis for standardizing genome detection of SARS-CoV-2

**Prof. Michael Neumaier**  
SARS-CoV-2 Antibody testing and the challenges in standardization of measurements: What we can learn from interlaboratory studies and what are the implications?

**Dr Michael A. Drebot**  
The development and assessment of Covid-19 serological platforms for serosurveillance and potential immunity correlation

**Guest Panel Member: Prof. Ian Young (JCTLM/IFCC).**

**Organizing Committee for webinar series: J. Huggett (LGC), J. Melanson (NRC), B. Guettler & G. O'Connor (PTB), J. Campbell (LGC), R. Wielgosz (BIPM), S-R. Park (CIPM).**

**Additional contributions from Webinar participants.**

### Contributors to production of the roadmap

**Steering Committee Members**

- Prof. Julian Braybrook - Chair, Steering Committee & Director, National Measurement Laboratory at LGC, UK
- Prof. Jim Huggett (Chair, CCQM NAWG)
- Dr Jeremy Melanson (Chair, CCQM PAWG)
- Dr Jonathan Campbell (Chair, CCQM CAWG)
- Dr Daniel Burke (NMIA)
- Dr Bernd Guettler & Prof. Gavin O’Connor (PTB)
- Dr Liana Dong & Hongmei Li (NIMC)
- Dr Young Bae (KRISS)
- Dr Michael Tarlov, Katrice Lippa & Dr Carlos Gonzalez (NIST)
- Dr Elena Kulyabina (VNIIMS)
- Dr Ralph Paroli (NRCC)
- Dr Robert Wielgosz & Dr Ralf Josephs (BIPM).

**Additional contributions from:**

- Webinar and workshop participants and broader consultation process.
General observations:

- Availability of automated qPCR for high-throughput platforms remains critically limited, especially for low- and middle-income countries.
- Performance against blinded panel of spiked clinical materials, given that implementation of multiple platforms to increase processing capacity resulted in inadvertent inefficiencies with multi-tasking between platforms and increased turnaround times (TAT).
- Optimization of analytical sensitivity across specimen types remains one of the greatest challenges; interest in alternatives may be at the expense of diagnostic accuracy, as comprehensive comparative performance data is currently unavailable.
- Correlations between specimen types in which SARS-CoV-2 is detected and organ system manifestations is required.

Take-home messages:

- Best is the enemy of (very) good! Emergency response requires ‘off the shelf’ response. QA/QC support is lagging behind operational response for an emergency situation. Can the community anticipate? What arrangements need to be in place? Invest in optimisation of laboratory methods in “peace” times. Create generic approaches for ensuring accurate measurement in future scenarios. Define scenarios, benchmarks, assay performance against stored pre-pandemic materials (specificity), dilution series of different control materials (probit analysis).
- Devise a global common terminology language, especially around measurement units.
- Identify level of infectiousness.
Gaps and solutions discussed during the CCQM Workshop and considered as identified QA needs:

<table>
<thead>
<tr>
<th>QA NEEDS</th>
<th>GAPS</th>
<th>FUTURE PLANNING</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calibrated virus materials</td>
<td>Pace &amp; agility to meet mass expansion</td>
<td>Rapid production of synthetic RNA</td>
</tr>
<tr>
<td>Synthetic RNA covering all targets</td>
<td>Distribution network</td>
<td></td>
</tr>
<tr>
<td>Diagnostic samples for evaluation work</td>
<td></td>
<td>Preparation of simulated clinical samples</td>
</tr>
<tr>
<td>Sample types &amp; sites</td>
<td>EQAs</td>
<td></td>
</tr>
<tr>
<td>Inventories</td>
<td>EQAs</td>
<td></td>
</tr>
<tr>
<td>Performance characteristics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Comparison studies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pilot surveillance</td>
<td></td>
<td></td>
</tr>
<tr>
<td>オープンソースソフトウェア開発の実施</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proficiency panels</td>
<td>Rapid feedback</td>
<td>Panel preparation</td>
</tr>
<tr>
<td>Material suitable for mass testing outside laboratories</td>
<td>Easily distributed materials</td>
<td>Commercial providers linked to standards</td>
</tr>
<tr>
<td>Materials which account for viral diversity</td>
<td>Rapid provision of international standards</td>
<td>Rapid scale-up</td>
</tr>
</tbody>
</table>

References

ISO 20395: 2019 Biotechnology - Requirements for evaluating the performance of quantification methods for nucleic acid target sequences - qPCR and dPCR


ISO17511:2020 In vitro diagnostic medical devices - Requirements for establishing metrological traceability of values assigned to calibrators, trueness control materials and human samples


EQAs

Low copy number controls
SMART analysis/middleware programmes for LIMS

Proficiency panels

Rapid feedback
Panel preparation

Material suitable for mass testing outside laboratories

Easily distributed materials
Commercial providers linked to standards

Materials which account for viral diversity

Rapid provision of international standards
Rapid scale-up


ISO/TS 5798:2022 In vitro diagnostic test systems - Requirements and recommendations for detection of SARS-CoV-2 by nucleic acid amplification methods
